作者: Meir Bialer , H. Steve White
DOI: 10.1038/NRD2997
关键词: Key factors 、 Intensive care medicine 、 Pharmacology 、 Refractory seizures 、 Epilepsy 、 Epileptogenesis 、 Disease 、 Medicine 、 Tolerability 、 Drug discovery 、 General Medicine
摘要: Despite an arsenal of antiepileptic drugs, ∼30% patients with epilepsy are not free from seizures. This article reviews the emerging understanding molecular basis and experimental models disease, how they might be used in design new therapeutics. Since early 1990s, many drugs (AEDs) that offer appreciable advantages terms their favourable pharmacokinetics, improved tolerability lower potential for drug–drug interactions have entered market. However, despite therapeutic old AEDs, approximately 30% still suffer Thus, there remains a substantial need development more efficacious AEDs refractory Here, we briefly review knowledge on pathological it best We also discuss current approach to AED discovery highlight some unique features newer pharmacoresistance epileptogenesis emerged recent years.